⭐ Summit Therapeutics, Inc. has reportedly been in partnership discussions with AstraZeneca and other major pharma companies for its sole asset, Ivonescimab (PD-1xVEGF BsAb) (Ref 1). ⭐ The potential deal, which could be valued at a staggering ~$15 billion (or higher?), would give a significant return on investment for Summit, which acquired the rights to ivonescimab from Akeso Biopharma in Dec 2022 in a transaction worth up to $5 billion, with a $500 million upfront payment (